HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $15 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.5%

Neg 0% Neu 88.5% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $15 price target.